BridgeBio Pharma Inc (BBIO)vsEli Lilly and Company (LLY)
BBIO
BridgeBio Pharma Inc
$72.44
-0.08%
HEALTHCARE · Cap: $14.62B
LLY
Eli Lilly and Company
$1,137.76
+1.98%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 11072% more annual revenue ($79.67B vs $713.07M). LLY leads profitability with a 33.5% profit margin vs -97.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
BBIO
Avoid31
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.0%
Fair Value
$636.90
Current Price
$72.44
$564.46 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 120.4% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -1790.0% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BBIO
The strongest argument for BBIO centers on Revenue Growth, Debt/Equity. Revenue growth of 120.4% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : BBIO
The primary concerns for BBIO are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
BBIO profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
BBIO carries more volatility with a beta of 0.97 — expect wider price swings.
BBIO is growing revenue faster at 120.4% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 31/100), backed by strong 33.5% margins and 47.7% revenue growth. BBIO offers better value entry with a 88.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BridgeBio Pharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?